1. A qualitative feasibility study to inform a randomised controlled trial of fluid bolus therapy in septic shock
- Author
-
O'Hara, CB, Canter, RC, Mouncey, P, Carter, A, Jones, N, Nadel, S, Peters, M, Lyttle, MD, Harrison, DA, Rowan, KM, Inwald, D, Woolfall, K, and NIHR Health Technology Assessment programme
- Subjects
MEDICAL-RESEARCH ,Male ,Parents ,PARTICIPATION ,CHILDREN ,Intensive Care Units, Pediatric ,Pediatrics ,PATIENT ,Ethics, Research ,1117 Public Health and Health Services ,sepsis ,Surveys and Questionnaires ,Humans ,INTERVIEWS ,CARE RESEARCH ,Child ,Qualitative Research ,intensive care ,Randomized Controlled Trials as Topic ,Science & Technology ,1103 Clinical Sciences ,EMERGENCY RESEARCH ,ethics ,Shock, Septic ,United Kingdom ,DEFERRED CONSENT ,Child, Preschool ,CONSULTATION ,Feasibility Studies ,Fluid Therapy ,1114 Paediatrics and Reproductive Medicine ,Female ,HEALTH ,Emergency Service, Hospital ,Life Sciences & Biomedicine - Abstract
Objective The Fluids in Shock (FiSh) Trial proposes to evaluate whether restrictive fluid bolus therapy (10 mL/kg) is more beneficial than current recommended practice (20 mL/kg) in the resuscitation of children with septic shock in the UK. This qualitative feasibility study aimed to explore acceptability of the FiSh Trial, including research without prior consent (RWPC), potential barriers to recruitment and participant information for a pilot trial. Design Qualitative interview study involving parents of children who had presented to a UK emergency department or been admitted to a paediatric intensive care unit with severe infection in the previous 3 years. Participants Twenty-one parents (seven bereaved) were interviewed 16 (median) months since their child’s hospital admission (range: 1–41). Results All parents said they would have provided consent for the use of their child’s data in the FiSh Trial. The majority were unfamiliar with RWPC, yet supported its use. Parents were initially concerned about the change from currently recommended treatment, yet were reassured by explanations of the current evidence base, fluid bolus therapy and monitoring procedures. Parents made recommendations about the timing of the research discussion and content of participant information. Bereaved parents stated that recruiters should not discuss research immediately after a child’s death, but supported a personalised postal ‘opt-out’ approach to consent. Conclusions Findings show that parents whose child has experienced severe infection supported the proposed FiSh Trial, including the use of RWPC. Parents’ views informed the development of the pilot trial protocol and site staff training. Trial registration number ISRCTN15244462—results.
- Published
- 2017